Johnson & Johnson (JNJ) Q3 2025 earnings summary

Executive summary

• Q3 2025 sales reached $24.0B, up 6.8% year-over-year, with operational growth of 5.4% and strong performance in both Innovative Medicine and MedTech segments.

• Net earnings for Q3 were $5.2B, up 91.2% year-over-year, with adjusted net earnings at $6.8B, up 15.7%.

• Growth was driven by double-digit gains in key brands, Oncology, Neuroscience, and Cardiovascular, as well as robust MedTech performance.

• Announced planned separation of the Orthopaedics business (DePuy Synthes) within 18–24 months to sharpen focus on high-growth, high-margin areas.

• Major acquisitions included Intra-Cellular Therapies ($14.5B) and Shockwave Medical ($12.6B), strengthening portfolios in neuroscience and MedTech.

Financial highlights

• Q3 worldwide sales were $24.0B, up 6.8% year-over-year; U.S. sales grew 6.2%, international sales 7.6%.

• Adjusted diluted EPS was $2.80, up 15.7% from Q3 2024; reported EPS was $2.12, up 91%.

• Gross margin for Q3 was 69.6%; free cash flow for Q3 was ~$14B; cash and equivalents at quarter-end were ~$19B.

• Debt at quarter-end was $45.8B, net debt position was $27.2B.

• Dividend per share was $1.30 for Q3, with continued quarterly dividends expected.

Outlook and guidance

• Raised full-year 2025 sales guidance to $93.7B at midpoint (5.7% growth); adjusted EPS guidance reaffirmed at $10.85.

• 2026 revenue growth expected to exceed 5%, with margin improvement anticipated.

• Orthopaedics separation targeted for completion in 18–24 months; expected to improve MedTech growth and margins by at least 75 bps.

• Ongoing restructuring in MedTech and Orthopaedics expected to be substantially completed by end of 2026 and 2025, respectively.